Abstract
In a recent article in the Journal of Clinical Oncology, Park and colleagues reported on neoadjuvant treatment response as an early indicator of response for patients with rectal cancer. In this pair of articles, JADPRO contributors discuss the implications of this study in terms of how assessment of response after neoadjuvant chemoradiotherapy impacts further management of the disease.
